[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Jiangsu HengRui Medicine Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":524},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,71,0,25,[9,43,65,85,108,131,151,173,194,213,233,254,274,294,313,333,352,371,390,408,429,447,467,486,504],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100603736","phase-1-a-study-of-hrs-4508-in-combination-with-other-anti-tumor-therapy-for-solid-tumor-100603736",false,"NCT07140393","A Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor","An Open, Multicenter Phase IB\u002FII Clinical Study of HRS-4508 in Combination With Other Anti-tumor Therapy for Solid Tumor","Inclusion Criteria:\n\n1. Age: 18 to 75 years old; Both men and women are welcome;\n2. The mixed cell types need to be confirmed by histology or cytology, and the dominant cell morphology, unresectable or metastatic .\n3. ECOG ratings of 0 or 1.\n4. Expected survival period ≥ 12 weeks.\n5. At least one measurable lesion outside the central nervous system that meets the RECIST v1.1 standard definition.\n6. Willing to participate and comply with the requirements of the research protocol, and willing to cooperate with follow-up visits.\n\nExclusion Criteria:\n\n1. Accompanied by untreated or active central nervous system (CNS) tumor metastasis. Subjects with a history of meningeal metastasis or current meningeal metastasis\n2. There have been significant severe infections and major surgeries in the past 4 weeks\n3. Existence of previous or concurrent malignant tumors\n4. Difficult to treat nausea, vomiting, or other gastrointestinal diseases that affect the use of oral medication\n5. Having undergone major surgeries other than diagnosis or biopsy within 28 days prior to the first administration;","ALL","18 Years","75 Years",{"count":21,"type":22},120,"ESTIMATED","INTERVENTIONAL",[25,26],"PHASE1","PHASE2","The study is being conducted to evaluate the efficacy, safety, and ORR of HRS-4508 combination with other anti tumor therapy in subjects with solid tumor ; to evaluate HRS-4508 DLT, MTD and RP2D, to evaluate the incidence and severity of adverse events (AE)\u002Fserious adverse events (SAE) (rated based on CTCAE v5.0), to evaluate ORR by researchers based on RECIST v1.1, to evaluate the pharmacokinetic (PK) characteristics of HRS-4508 SHR-1811, Capecitabine.",[29],"Solid Tumor","RECRUITING","2026-06-25",{"date":33,"type":34},"2026-06-29","ACTUAL",{"date":36,"type":34},"2025-10-28",{"date":38,"type":22},"2028-10",{"name":40,"class":41},"Jiangsu HengRui Medicine Co., Ltd.","INDUSTRY",1,{"id":44,"slug":45,"hasResults":12,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":12,"sex":50,"minAge":18,"maxAge":19,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":42},"100591015","phase-1-a-clinical-study-of-hrs-6209-combined-with-other-treatment-regimens-in-patients-with-breast-cancer-100591015","NCT06974929","A Clinical Study of HRS-6209 Combined With Other Treatment Regimens in Patients With Breast Cancer","An Open-Label, Multicenter Phase Ib\u002FII Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HRS-6209 Combination Therapy in Patients With Breast Cancer","Inclusion Criteria:\n\n1. Women aged 18-75 years.\n2. ECOG performance status 0-1.\n3. Menopausal status.\n4. Evidence of radiographic disease progression during or after the last systemic anti-tumor therapy prior to the first study drug administration.\n5. At baseline, there must be at least one measurable, extracranial lesion that meets RECIST v1.1 criteria.\n6. Expected survival \\> 3 months.\n7. Women of childbearing potential must agree to use highly effective contraceptive measures during the study treatment and for 6 months after the end of treatment. Women of childbearing potential must have a negative serum HCG test within 7 days prior to study enrollment and must not be breastfeeding.\n8. Voluntarily agree to participate in this clinical trial, willing and able to comply with the study visits and procedures, understand the study procedures, and have signed the informed consent form.\n\nExclusion Criteria:\n\n1. Symptomatic visceral metastasis and other conditions, and the researcher judged that endocrine therapy was not suitable for use.\n2. History of clinically serious cardiovascular disease.\n3. The ECG examination was abnormal.\n4. Patients with clinically significant endometrial abnormalities, including but not limited to endometrial hyperplasia and dysfunctional uterine bleeding.\n5. The subjects were in acute infection or active tuberculosis and needed drug treatment.\n6. The patients received surgery, chemotherapy, immunotherapy and macromolecular targeted therapy within 4 weeks before the first medication.\n7. Pregnant and lactating women, or intending to become pregnant during the study.\n8. There was a clear history of neurological or mental disorders and the subjects had a history of psychotropic drug abuse or drug abuse.\n9. In the course of this study, it is expected to receive other anti-tumor treatments or drugs.","FEMALE",{"count":52,"type":22},80,[25,26],"This is a study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HRS-6209 combined with other treatment regimens in breast cancer patients, and preliminarily observe its anti-tumor efficacy.",[56],"Breast Cancer","2026-06-10",{"date":59,"type":34},"2026-06-12",{"date":61,"type":34},"2025-05-22",{"date":63,"type":22},"2026-12",{"name":40,"class":41},{"id":66,"slug":67,"hasResults":12,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":72,"targetDuration":4,"studyType":23,"phases":74,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":42},"100635756","phase-1-phase-i-study-of-hrs-3005-in-b-cell-malignancies-100635756","NCT07556822","Phase I Study of HRS-3005 in B-cell Malignancies","An Open-Label, Multicenter, Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HRS-3005 in Patients With B-cell Malignancies","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1;\n3. Life expectancy ≥12 weeks;\n4. Histologically or cytologically confirmed relapsed\u002Frefractory B-cell malignancies;\n5. Measurable disease;\n6. Adequate organ function;\n7. Females of childbearing potential must not be pregnant or lactating. Females of childbearing potential and males with partners of childbearing potential must agree to use effective contraception from the time of informed consent until 28 days after the last dose of study treatment;\n8. Voluntary participation with signed informed consent, good compliance, and willingness to complete follow-up visits.\n\nExclusion Criteria:\n\n1. Known central nervous system (CNS) involvement by malignancy;\n2. History of other malignancy within 2 years prior to first dose of study drug, except for the disease under study;\n3. Prior autologous stem cell transplantation or CAR-T therapy within 12 weeks before first dose of study drug;\n4. Prior allogeneic hematopoietic stem cell transplantation;\n5. Positive hepatitis B surface antigen (HBsAg) with detectable HBV-DNA at screening;\n6. Positive hepatitis C antibody with detectable HCV-RNA at screening;\n7. Positive HIV antigen\u002Fantibody test at screening;\n8. Active fungal, bacterial, and\u002For viral infection requiring systemic therapy;\n9. Major surgery or significant trauma within 28 days prior to first dose of study drug;\n10. Severe disease of major organ systems;\n11. Prior anti-tumor treatment-related adverse events not recovered to ≤Grade 1 or stable status;\n12. Incomplete washout period from prior anti-tumor therapy before first dose of study drug;\n13. Use of strong or moderate CYP3A inducers, or strong or moderate CYP3A inhibitors within 14 days prior to first dose of study drug;\n14. Live vaccine administration within 28 days prior to first dose of study drug;\n15. Ongoing alcohol or drug abuse;\n16. Intracranial hemorrhage within 6 months prior to first dose of study drug;\n17. Currently receiving vitamin K antagonists or Factor Xa inhibitors;\n18. History of severe bleeding disorder, such as coagulation factor deficiency or von Willebrand factor (vWF) deficiency;\n19. Inability to swallow oral medication, or presence of severe gastrointestinal disease or prior surgery significantly affecting gastrointestinal function;\n20. Pregnant or lactating females;\n21. Concurrent participation in another interventional clinical study, or less than 1 month between signing informed consent and last dose of previous clinical study.",{"count":73,"type":22},190,[25],"The study is being conducted to evaluate the safety and tolerability of HRS-3005. To explore the Maximum Tolerated Dose (MTD, if possible) and the Recommended Phase 2 Dose (RP2D). This study also preliminarily evaluated the efficacy of HRS-3005 in patients with B-cell malignancy.",[77],"B-cell Malignancy","2026-06-08",{"date":57,"type":34},{"date":81,"type":34},"2026-06-03",{"date":83,"type":22},"2028-12",{"name":40,"class":41},{"id":86,"slug":87,"hasResults":12,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":12,"sex":92,"minAge":18,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":23,"phases":96,"briefSummary":97,"conditions":98,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":107},"100559742","phase-1-a-study-of-hrs-5041-tablets-combined-with-antitumor-therapy-in-subjects-with-advanced-prostate-cancer-100559742","NCT06568094","A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer","An Open, Multicenter Phase Ib\u002FII Study on the Safety, Tolerability and Efficacy of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer","Inclusion Criteria:\n\n1. Have the ability to give informed consent, and are willing and able to comply with planned visits for medical examinations and other procedural requirements.\n2. The age is above 18 years old when signing the informed consent (the ceiling age is 80 years old in the dose escalation phase), male.\n3. ECOG score is 0 or 1.\n4. An expected survival of ≥ 12 weeks.\n5. Adenocarcinoma of the prostate confirmed with histologically or cytologically ,and without a diagnosis of neuroendocrine or small cell carcinoma.\n6. Adequate blood samples should be provided for gene mutation detection during the screening period. It is recommended to provide tumor tissue samples.\n7. Male subjects whose partner is women of childbearing potential (WOCBP) are required to use highly effective contraception from the date of signing the informed consent until 3 months after the last dose of the investigational drug.\n\nExclusion Criteria:\n\n1. Plan to receive any other antitumor therapy during this study.\n2. Had history of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML); Or had other malignancies in the 5 years prior to the first dose.\n3. Participants who are participating in another clinical study or whose first dose is less than 4 weeks from the end of the previous clinical study (last dose), or five half-lives of the investigational drug, whichever is shorter.\n4. Had undergone major surgery within 28 days prior to first dosing; Minor traumatic surgery within 7 days prior to first dosing; There are non-healing wounds, untreated fractures.\n5. Drugs with a strong inducer or inhibitor of the metabolic enzyme CYP3A have been used in the past, and the washout period from the end time to the first administration in this study is shorter than the 5 half-life of the drug.\n6. The toxicity from previous anti-tumor treatment has not recovered to ≤ grade I.\n7. Central nervous system or meningeal metastasis of tumors is known or subjects have a history of primary central nervous system tumors.\n8. Severe cerebrovascular disease occurred within 6 months prior to administration.\n9. Subjects with poorly controlled hypertension and a history of hypertensive crisis or hypertensive encephalopathy.\n10. Severe bone injury due to bone metastases, pathological fractures , and spinal cord compression as determined by the investigators at important sites that occurred within the last 6 months or are expected to occur in the near future.\n11. Having one of multiple factors that affect the oral drug or having an active gastrointestinal disease or other disease that may significantly affect drug absorption, distribution, metabolism, or excretion.\n12. Had history of allergy to the proposed investigational drug or its excipient components.\n13. Presence of active heart disease in the 6 months prior to first dosing, including severe\u002Funstable angina, myocardial infarction, symptomatic congestive heart failure, and medically treatable ventricular arrhythmias.\n14. Presence of active hepatitis B and hepatitis C; Or serious infected persons requiring antibiotics, antivirals or antifungal drugs to control.\n15. Presence of the history of immunodeficiency or organ transplantation.\n16. Presence of other serious physical or mental diseases or laboratory abnormalities.","MALE","80 Years",{"count":95,"type":22},100,[25,26],"The purpose of this study is to evaluate the efficacy, and safety of HRS-5041 tablets combined with antitumor therapy in subjects with advanced prostate cancer.",[99],"Prostate Cancer","2026-06-07",{"date":57,"type":34},{"date":103,"type":34},"2024-09-25",{"date":105,"type":22},"2027-06",{"name":40,"class":41},2,{"id":109,"slug":110,"hasResults":12,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":115,"sex":17,"minAge":18,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":23,"phases":119,"briefSummary":120,"conditions":121,"keywords":4,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":42},"100638997","phase-1-a-study-to-estimate-effect-of-formulation-and-food-on-relative-bioavailability-of-hrs-6209-in-healthy-participants-100638997","NCT07610148","A Study to Estimate Effect of Formulation and Food on Relative Bioavailability of HRS-6209 in Healthy Participants","A Single-Center, Single-Dose, Randomized, Open-Label, Three-Period, Three-Sequence, Crossover Study to Evaluate the Oral Relative Bioavailability of Old and New Formulations of HRS-6209 Capsules and the Effect of Food in Healthy Chinese Participants","Inclusion Criteria:\n\n1. Healthy men and women aged 18 to 50 years old at informed consent signing.\n2. Male body weight ≥ 50 kg, female ≥ 45 kg; BMI 19 to 26 kg\u002Fm² at screening and baseline.\n3. Have no clinically significant abnormalities at screening and baseline.\n4. Fertile females and males with fertile female partners: effective contraception 2 weeks before consent, and sustained until 6 months after the last dose (abstinence or highly effective contraception); no sperm\u002Fegg donation.\n\nExclusion Criteria:\n\n1. Current or history of clinically significant disorders of any major system (urinary, circulatory, endocrine, nervous, digestive, respiratory, hematologic, immune, psychiatric, metabolic, etc.) or any other condition that may interfere with study results per investigator judgment.\n2. History of epilepsy, including febrile seizures in childhood, loss of consciousness, transient ischemic attack, or any condition predisposing to seizures (e.g., cerebrovascular disease, brain injury, stroke, brain cancer).\n3. Clinically significant acute illness within 1 month prior to screening, including fever or febrile symptoms, viral, bacterial (including upper respiratory tract infection), or non-cutaneous fungal infections.\n4. Any surgery within 6 months prior to study, or planned surgery during study period; prior surgery affecting gastrointestinal absorption (including gastrectomy, bowel resection, bariatric surgery) or affecting liver function.\n5. Positive for anti-HCV, anti-HIV, HBsAg, or syphilis antibodies.\n6. Blood donation or loss ≥ 400 mL within 3 months, or ≥ 200 mL within 1 month prior to screening; blood transfusion or use of blood products within 3 months prior to screening.\n7. Long-term use (\\> 7 consecutive days) of hepatotoxic drugs within 6 months; use of any drug affecting liver metabolism within 1 month prior to first dose; use of other drugs (prescription, OTC, herbal, vitamins, calcium, etc.) within 14 days prior to first dose, other than those affecting liver metabolism.\n8. Participation in another clinical trial with investigational drug within 3 months; vaccination within 3 months prior to screening or planned during study.\n9. History of drug abuse\u002Fdependence; positive urine drug screen at screening.\n10. History of heavy smoking (average ≥ 5 cigarettes\u002Fday) within 3 months prior to screening; inability to abstain from any tobacco products during study; positive smoke screen.\n11. Alcoholism (average daily intake exceeding: \\> 14 units\u002Fweek; 1 unit = 285 mL beer, 25 mL spirits, or 100 mL wine); positive alcohol screen; inability to abstain from alcohol during study.\n12. Special dietary requirements or inability to comply with standardized meals.\n13. Dysphagia, difficulty with venous blood collection, or inability to tolerate intensive blood sampling.\n14. Other conditions that, in the investigator's judgment, make the participant unsuitable for the study.",true,"50 Years",{"count":118,"type":22},21,[25],"This is a phase 1, randomised, open-label, three-way, three-period, crossover relative bioavailability study to assess the pharmacokinetics of HRS-6209 capsules (old and new formulation) in healthy participants. The effect of high-fat food on the pharmacokinetics of HRS-6209 in new formulation will also be evaluated. A total of 21 healthy participants will be randomised to receive a single oral dose of HRS-6209 in three treatment periods: old formulation (fasted); new formulation (fasted); new formulation (fasted).",[56],"NOT_YET_RECRUITING","2026-05-20",{"date":125,"type":34},"2026-05-27",{"date":127,"type":22},"2026-05",{"date":129,"type":22},"2026-06",{"name":40,"class":41},{"id":132,"slug":133,"hasResults":12,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":23,"phases":140,"briefSummary":141,"conditions":142,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":149,"locationsCount":150},"100460556","phase-1-a-trial-to-evaluate-the-safety-tolerability-pharmacokinetics-and-efficacy-of-shr-a1904-in-subjects-with-advanced-solid-tumors-100460556","NCT05277168","A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS","AN OPEN-LABEL, SINGLE-ARM, MULTI-CENTER PHASE I\u002FIIA CLINICAL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS","Inclusion Criteria:\n\n1. Evidence of a personally signed and dated ICF indicating that the subject has been informed of all pertinent aspects of the study.\n2. Age \\> 18.\n3. ECOG performance status of 0-1.\n4. Life expectancy of ≥ 3 months.\n5. Subjects with pathologically diagnosed advanced relapsed or refractory solid tumors, either gastric and gastroesophageal junction (GEJ) cancer, or pancreatic cancer, who are intolerable to SoC, have progressed through all available treatment options, or for whom there is no efficacious treatment available. Subjects must have pathological classification (e.g., adenocarcinoma etc.) documented.\n6. Positive expression of Claudin 18.2 (\\>= 50% of cells with 2+ or 3+ expression, either from fresh or archival tissue) is required prior to enrollment and participation in this study. Positivity for Claudin 18.2 is defined as tumor cells showing partial or complete membrane staining. The percentage of tumor cells at four different staining intensities will be estimated: 0 (no staining), 1+ (weak), 2+ (moderate), and 3+ (strong). The sum of all 4 percentages should equal 100%. The H-score is determined according to the H-Score formula: \\[1 x Percentage of tumor cells stained at 1+\\] + \\[2 x Percentage of tumor cells stained at 2+\\] + \\[3 x Percentage of tumor cells stained at 3+\\] = H-Score (range 0 or 1-300). Actual figure of Claudin 18.2 expression tested by IHC should be documented. Subjects must have pathological classification (e.g., adenocarcinoma) documented.\n7. Has at least one measurable lesion as defined by RECIST v1.1.\n8. Has adequate organ and bone marrow function within 7 days prior to administration of study treatment defined below: with no blood transfusion or hematopoietic growth factor support within 2 weeks prior to screening): • Absolute neutrophil count (ANC) ≥1.5 × 109 \u002FL • Platelet count (PLT) ≥ 100 × 109 \u002FL • Hemoglobin (Hb) ≥ 90 g\u002FL • TBIL ≤1.5 × ULN • ALT and AST ≤ 3 × ULN (≤ 5 × ULN for liver metastasis) • Creatinine clearance ≥ 60 mL\u002Fmin\u002F1.73 m2 based on Cockcroft-Gault equation (Appendix 5) • Activated partial thromboplastin time (APTT) and prothrombin time (PT) ≤ 1.5 × ULN. • Fridericia-corrected QT interval (QTcF) ≤ 450 msec. If ECG demonstrates QTc \\> 450 msec at screening, an ECG re-examination is allowed, and subjects will be eligible if it demonstrates QTc ≤ 450 msec. • LVEF ≥ 50%.\n9. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 3 days before the first dose. WOCBP and male subjects whose partners are WOCBP must agree to use effective contraception method during the study period and within 5 half-lives of SHR-A1904 + 6 months after the last dose of SHR-A1904.\n\nExclusion Criteria:\n\n1. Plan to receive any other anti-tumor treatments during the treatment period of this study.\n2. Subjects participated in a prior investigational study or received anticancer treatment, and have not recovered from side effects of such therapy.\n3. Underwent major surgical operation within 4 weeks before the first dose of this IP.\n4. Received treatments with strong CYP3A4, CYP2D6, P-gp, or BCRP inhibitors or inducers within \\\u003C 5 half-lives of the drug before the first dose of the study.\n5. Previously received total gastrectomy (only for subjects of the dose-escalation part.\n6. Adverse events caused by previous anti-tumor treatments have not recovered to Grade ≤ 1 according to NCI-CTCAE 5.0 (except for alopecia; some tolerable chronic Grade 2 toxicities may also be excluded as judged by the investigator after consultation with the sponsor).\n7. Known to be allergic to any component of SHR-A1904 product (antibody conjugated toxin, antibody), or allergic to humanized monoclonal antibody products.\n8. Subjects with known brain metastases, unless the participant is \\> 1 month from definitive therapy (surgery or radiotherapy), has no evidence of tumor growth on an imaging study and is clinically stable with respect to the tumor at the start of study intervention.\n9. Subjects with a second primary cancer, except adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, and other solid tumors curatively treated with no evidence of disease for ≥ 3 years prior to the first dose of the study.\n10. Class III-IV cardiac insufficiency as per the New York Heart Association (NYHA) criteria; arrhythmia requiring long-term drug control; unstable angina or acute myocardial infarction within 6 months before the first dose of the study.\n11. Subjects with a history of clinically significant lung diseases (e.g., interstitial pneumonia, radiation pneumonia, and pulmonary fibrosis) or who are suspected to have these diseases by chest imaging at screening period.\n12. Serious infections that require use of intravenous antibiotics, antiviral drugs, or antifungal drugs during the study period.\n13. Hepatitis B (HBV, chronic or acute; defined as having a known positive hepatitis B surface antigen \\[HbsAg\\] test at the time of screening) or hepatitis C (HCV) infection requiring treatment.\n14. Has a history of immunodeficiency (including positive results of HIV test in screening, and other acquired and congenital immunodeficiencies) or organ transplant.\n15. Presence of accompanying diseases (such as poorly controlled hypertension, serious diabetes mellitus, thyroid disorder, psychosis, etc.) that may pose serious risks to the safety of the subject or may affect the subject's ability to complete the study, or any other situation as judged by the investigator.",{"count":139,"type":22},83,[25,26],"The study (dose escalation\u002Fexpansion) is being conducted to assess the safety and tolerability of SHR-A1904 in subjects with advanced solid tumors, and to determine maximum tolerated dose (MTD) and\u002For recommended phase II dose (RP2D), to assess preliminary efficacy of SHR-A1904, pharmacokinetic (PK) profile and immunogenicity of SHR-A1904 in subjects with advanced solid tumors.",[143],"Advanced Solid Tumors",{"date":145,"type":34},"2026-05-22",{"date":147,"type":34},"2022-05-30",{"date":127,"type":22},{"name":40,"class":41},28,{"id":152,"slug":153,"hasResults":12,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":158,"targetDuration":4,"studyType":23,"phases":160,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":107},"100507197","phase-3-an-open-label-phase-3-study-of-lutetium-177lu-oxodotreotide-injection-in-subjects-with-advanced-gastrointestinal-pancreatic-neuroendocrine-tumors-100507197","NCT05884255","An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.","Randomized, Open, Positive Control Phase III Clinical Trial of Lutetium (177Lu) Oxodotreotide Injection Combined With Standard-dose Long-acting Octreotide Versus High-dose Long-acting Octreotide in the Treatment of Somatostatin Receptor-positive Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.","Inclusion Criteria:\n\n1. Able and willing to provide a written informed consent;\n2. 18\\~75 years old,male or female;\n3. ECOG performance status 0 or 1;\n4. Unresectable locally advanced or metastatic gastrointestinal neuroendocrine tumors (GEP-NETs) of low and medium grade (G1 or G2) confirmed by histopathology.\n\nExclusion Criteria:\n\n1. Central nervous system metastasis is known. Patients who have previously received treatment ( radiotherapy or surgery ) for brain metastases and have no clinical symptoms can be enrolled if the pre-randomized pre-imaging is confirmed to be stable for at least 24 weeks;\n2. There are clinical symptoms or diseases of the heart that are not well controlled;\n3. Diabetes (fasting blood glucose \\> 2 × ULN) that cannot be well controlled after optimal medical support treatment;\n4. Severe urinary incontinence, hydronephrosis, severe micturition dysfunction or indwelling catheter for any reason.",{"count":159,"type":22},220,[161],"PHASE3","The study is being conducted to evaluate the efficacy, and safety of Lutetium (177Lu) Oxodotreotide Injection in subjects with advanced gastrointestinal pancreatic neuroendocrine tumors.",[164],"Advanced Gastroenteropancreatic Neuroendocrine Tumor","2026-05-15",{"date":167,"type":34},"2026-05-19",{"date":169,"type":34},"2023-07-06",{"date":171,"type":22},"2030-10",{"name":40,"class":41},{"id":174,"slug":175,"hasResults":12,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":12,"sex":50,"minAge":18,"maxAge":19,"enrollmentInfo":180,"targetDuration":4,"studyType":23,"phases":182,"briefSummary":183,"conditions":184,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":188,"startDateStruct":190,"completionDateStruct":192,"leadSponsor":193,"locationsCount":42},"100631185","phase-2-a-trial-of-trastuzumab-rezetecan-in-unresectable-locally-recurrentmetastatic-breast-cancer-100631185","NCT07497386","A Trial of Trastuzumab Rezetecan in Unresectable Locally Recurrent\u002FMetastatic Breast Cancer","A Randomized, Open-Label, Multicenter Phase II Clinical Study of Different Doses of Trastuzumab Rezetecan for Injection or Trastuzumab Deruxtecan for Injection in the Treatment of Unresectable Locally Recurrent\u002FMetastatic Breast Cancer With HR-Positive and HER2-Low Expression","Inclusion Criteria:\n\n1. Female aged 18 to 75 years (inclusive).\n2. Unresectable locally recurrent or metastatic breast cancer.\n3. Prior therapy must meet the following: No prior chemotherapy for recurrent\u002Fmetastatic disease. Must have received at least one prior line of endocrine therapy for recurrent\u002Fmetastatic disease with disease progression, and the investigator judges that further benefit from endocrine therapy is not possible.\n4. Documented radiological disease progression (during or after the most recent therapy).\n5. ECOG performance status of 0 or 1.\n6. Life expectancy ≥ 12 weeks.\n7. At least one extracranial measurable lesion as a target lesion according to RECIST v1.1 criteria.\n8. Adequate function of major organs.\n9. Pregnancy and contraception: Women of childbearing potential (WOCBP) must agree to use highly effective contraception from study screening until 7 months after the last dose of study drug and agree not to breastfeed; serum pregnancy test result must be negative within 7 days before the first dose.\n10. The patient voluntarily participates in this study, signs the informed consent form, has good compliance, and is willing to cooperate with visits and study-related procedures.\n\nExclusion Criteria:\n\n1. Presence of leptomeningeal metastasis\u002Fcarcinomatous meningitis, spinal cord compression, or active central nervous system metastases.\n2. Patients with only skin or brain lesions as target lesions.\n3. History of other malignancies within the past 5 years, except for cured basal cell carcinoma of the skin or carcinoma in situ of the cervix.\n4. Presence of carcinomatous lymphangitis, or third-space fluid accumulation that cannot be controlled by methods such as drainage.\n5. Prior surgery, chemotherapy, immunotherapy, or macromolecular targeted therapy within 4 weeks before the first dose; prior endocrine therapy, chemotherapy with 5-FU analogs, or radiotherapy within 2 weeks before the first dose; small molecule targeted agents require a washout period of 2 weeks or 5 half-lives; other investigational drugs require a washout period of 4 weeks or 5 half-lives before the first dose.\n6. Use of immunosuppressants or systemic corticosteroids for immunosuppressive purposes within 2 weeks before the first dose for therapeutic intent.\n7. History of immunodeficiency, including a positive HIV test, other acquired or congenital immunodeficiency diseases, or history of organ transplantation.\n8. Clinically significant cardiovascular disease, such as severe\u002Funstable angina, symptomatic congestive heart failure, etc.; clinically significant supraventricular or ventricular arrhythmia requiring treatment or intervention; myocardial infarction or cerebrovascular accident within 6 months before the first dose.\n9. Participants with known or suspected interstitial lung disease; other moderate-to-severe pulmonary diseases that may interfere with the detection or management of drug-related pulmonary toxicity and severely affect respiratory function within 3 months before the first dose; and any autoimmune, connective tissue, or inflammatory disorders with pulmonary involvement.\n10. Known hereditary or acquired bleeding tendency.\n11. Active hepatitis B, hepatitis C, or cirrhosis; or severe infection requiring control with antibiotics, antivirals, or antifungals.\n12. Toxicities from prior anti-tumor therapy have not recovered to ≤ Grade 1 (according to NCI-CTCAE v5.0).\n13. Any other severe physical or mental illness or laboratory abnormality that may increase the risk associated with study participation, interfere with study results, or any other condition for which the investigator considers the patient unsuitable for participation in this study.",{"count":181,"type":22},150,[26],"The study is designed to compare the efficacy and safety of different dose groups of Trastuzumab Rezetecan or Trastuzumab Deruxtecan in patients with HR-positive, HER2-low unresectable locally recurrent\u002Fmetastatic breast cancer. It will also exploratively evaluate the pharmacokinetic profile and immunogenicity of Trastuzumab Rezetecan.",[185,186],"Unresectable Locally Recurrent Breast Cancer","Unresectable Locally Metastatic Breast Cancer","2026-05-07",{"date":189,"type":34},"2026-05-11",{"date":191,"type":34},"2026-04-28",{"date":83,"type":22},{"name":40,"class":41},{"id":195,"slug":196,"hasResults":12,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":12,"sex":92,"minAge":18,"maxAge":4,"enrollmentInfo":201,"targetDuration":4,"studyType":23,"phases":203,"briefSummary":204,"conditions":205,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":187,"lastUpdatePostDateStruct":207,"startDateStruct":208,"completionDateStruct":210,"leadSponsor":212,"locationsCount":42},"100611502","phase-3-a-phase-iii-clinical-study-of-rezvilutamide-in-patients-with-metastatic-hormone-sensitive-prostate-cancer-100611502","NCT07241416","A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer","A Multicenter, Randomized, Open-Label, Positive-Controlled Phase III Study of Rezvilutamide Combined With Androgen Deprivation Therapy (ADT) Versus Enzalutamide Combined With ADT for Treating Low-volume Metastatic Hormone Sensitive Prostate Cancer (mHSPC)","Inclusion Criteria:\n\n1. Voluntarily participates in this clinical trial, with an understanding of the study procedures and signed informed consent;\n2. Age ≥ 18 years;\n3. Histologically or cytologically confirmed prostate adenocarcinoma without evidence of neuroendocrine differentiation or small cell features;\n4. Metastatic hormone sensitive prostate cancer;\n5. ECOG PS: 0-1;\n6. Planned to receive and maintain ADT during the study period;\n7. Adequate hepatic, renal, heart, and hematological functions;\n8. Determined by the investigator to be able to comply with the study protocol;\n9. Fertile subjects must use effective contraception or abstain from sexual activity and sperm donation until 3 months after last exposure to rezvilutamide or enzalutamide. Subjects must use condoms plus an additional effective contraceptive method during sexual activity with a fertile female partner throughout treatment and for 3 months post-treatment.\n\nExclusion Criteria:\n\n1. Prior treatment with ADT, chemotherapy, surgery, external-beam radiotherapy, brachytherapy, radiopharmaceuticals, or investigational local therapy for metastatic prostate cancer, except as specifically allowed by the protocol;\n2. Previous use of second-generation androgen receptor antagonists, ketoconazole, abiraterone acetate, or other investigational drugs inhibiting androgen synthesis for prostate cancer treatment; or plans to use any second-generation androgen receptor antagonist other than the study drug during the study treatment period;\n3. Total PSA has decreased to undetectable levels at baseline;\n4. Have participated in an interventional clinical trial or been treated with the following drugs in the past 4 weeks before randomization: 5-alpha reductase inhibitors, estrogen, progestin, and herbal products known to decrease PSA levels;\n5. Planned to initiate any other anti-tumor therapies during the study;\n6. Known history of hypersensitivity to rezvilutamide, enzalutamide, or any of their components;\n7. Unable to swallow, chronic diarrhea or intestinal obstruction, or the presence of a variety of other factors that affect drug use and absorption;\n8. History of seizure or certain conditions that may predispose to seizure;\n9. Presence of clinically significant cardiovascular diseases within 6 months prior to randomization;\n10. Any other malignancy within 5 years prior to randomization (except as specifically allowed by the protocol);\n11. Active HBV or HCV infection;\n12. History of immunodeficiency (including HIV-positive status, other acquired or congenital immunodeficiency disorders) or organ transplantation;\n13. Any concomitant condition that, in the opinion of the investigator, would seriously jeopardize patient safety, confound study findings, or compromise the patient's ability to complete the study (e.g., hypertension inadequately controlled despite medication, severe diabetes, neurologic or psychiatric disorders, etc.) or any other circumstance.",{"count":202,"type":22},206,[161],"This study aims to compare the efficacy and safety of rezvilutamide with enzalutamide in the treatment of patients with low-volume metastatic hormone sensitive prostate cancer.",[206],"Metastatic Hormone-sensitive Prostate Cancer (mHSPC)",{"date":189,"type":34},{"date":209,"type":34},"2025-12-05",{"date":211,"type":22},"2028-09",{"name":40,"class":41},{"id":214,"slug":215,"hasResults":12,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":4,"eligibilityCriteria":219,"healthyVolunteers":115,"sex":17,"minAge":18,"maxAge":220,"enrollmentInfo":221,"targetDuration":4,"studyType":23,"phases":223,"briefSummary":224,"conditions":225,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":232,"locationsCount":42},"100630577","phase-1-a-clinical-study-comparing-the-relative-bioavailability-and-safety-of-shr-3167-injection-100630577","NCT07489482","A Clinical Study Comparing the Relative Bioavailability and Safety of SHR-3167 Injection","A Randomized, Parallel, Open-label Clinical Study on the Bioavailability and Safety of Different Specifications of SHR-3167 Injection in Healthy Subjects","Inclusion Criteria:\n\n1. Male or female: 18 years old to 55 years old (on the day of signing the informed consent form).\n2. For healthy subjects, the body mass index (BMI) should be between 19.0 kg\u002Fm² and 26.0 kg\u002Fm², and the weight of men should be ≥ 50 kg and that of women ≥ 45 kg.\n3. Those who show no abnormalities through physical examination, vital signs, 12-lead electrocardiogram, frontal and lateral chest radiographs and laboratory tests, or have minor abnormalities but are judged by the researcher to have no clinical significance.\n4. Female subjects of childbearing potential or male subjects whose partners are of childbearing potential must have no plans for conception or sperm\u002Fegg donation from the time of signing the informed consent form until 4 months after the last dose, and must voluntarily refrain from unprotected sexual activity within 14 days before the screening period and use effective contraceptive measures (including partners) during the study period; female subjects of childbearing potential must have no unprotected sexual activity in the past 14 days, have a negative pregnancy test during the screening period, and not be in the lactation period.\n5. During the screening process, the fasting blood glucose should be between 3.9 mmol\u002FL and 6.1 mmol\u002FL, and the glycated hemoglobin (HbA1c) should be no more than 6.0%.\n6. Understand the research procedures and methods, voluntarily participate and have the ability to comply with the requirements of the trial protocol to complete this trial, and sign the informed consent form in person.\n\nExclusion Criteria:\n\n1. Those with a history of frequent allergies or allergic diseases, or those who, as judged by the researcher, may be allergic to the study drug or its components or foods, etc.\n2. Those who have previously suffered from respiratory system, circulatory system, digestive system, urinary system, mental, nervous system, blood system, endocrine system, immune system or malignant tumor diseases, and who, based on the investigator's judgment, are not suitable to participate in this trial.\n3. Exclude those who had severe infections, severe injuries or surgeries within the previous 12 weeks, or those who plan to undergo surgery during the trial.\n4. Exclude those who have participated in any clinical trials of other drugs or medical devices within the previous 3 months prior to screening, or those who are still within 5 half-lives of the trial drug at the time of screening (whichever is longer).\n5. Exclude those who have used any medication (including prescription drugs, over-the-counter drugs, herbal medicines, patent medicines, health supplements, etc.) within the previous 2 weeks up to the time of randomization.\n6. Positive results were obtained for hepatitis B surface antigen (HBsAg), HIV antibody, Treponema pallidum specific antibody, or hepatitis C virus antibody tests; or the investigator judged that the subject was in the latent or active stage of the aforementioned infections.\n7. Exclude those who have a history of blood donation within the past 12 weeks, or have suffered from severe blood loss (blood loss ≥ 400 mL), or have received blood transfusion within the past 12 weeks.\n8. Those who received live (attenuated) vaccines within the previous 1 month or are scheduled to receive such vaccines during the trial process.\n9. Those who have a history of drug use or substance abuse; or those who tested positive for drugs in the baseline visit.\n10. Those who have difficulty in venous blood collection or whose physical condition does not allow for blood collection; or those who are expected not to comply well with the protocol or complete the entire trial follow-up.\n11. Persons with incomplete civil capacity and without a valid guardian.\n12. The researchers determined that any physical or psychological condition or illness that might increase the risk of the trial, affect the subjects' compliance with the protocol, or prevent the subjects from completing the trial.","55 Years",{"count":222,"type":22},60,[25],"This study is a randomized, parallel, open-label Phase I clinical trial aimed at comparing the bioavailability and safety of different specifications of SHR-3167 injection, with healthy subjects as the research subjects.",[226],"Diabetes Mellitus",{"date":228,"type":34},"2026-04-29",{"date":230,"type":34},"2026-04-02",{"date":63,"type":22},{"name":40,"class":41},{"id":234,"slug":235,"hasResults":12,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":23,"phases":241,"briefSummary":242,"conditions":243,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":245,"lastUpdatePostDateStruct":246,"startDateStruct":248,"completionDateStruct":250,"leadSponsor":252,"locationsCount":253},"100614933","phase-3-a-study-to-evaluate-the-efficacy-and-safety-of-hetrombopag-olamine-tablets-vs-placebo-in-patients-with-chemotherapy-induced-thrombocytopenia-100614933","NCT07286032","A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia","A Randomized, Multi-Center, Double-Blind, Phase III Study Evaluating the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia","Inclusion Criteria:\n\n1. Male or female gender, age ≥18 years at screening.\n2. Histologically or cytologically confirmed solid tumor (e.g., non-small-cell lung carcinoma \\[NSCLC\\], breast, ovarian, bladder, pancreatic, gastrointestinal, or colon\u002Fcolorectal cancer).\n3. Receiving platinum- and\u002For gemcitabine-containing chemotherapy regimens on 21-day treatment cycles.\n4. Eastern Cooperative Oncology Group performance status (ECOG PS) 0-2.\n5. Life expectancy ≥6 months.\n6. Signed ICF for voluntary participation in the study and good compliance.\n\nExclusion Criteria:\n\n1. Hematopoietic diseases other than CIT (e.g., primary immune thrombocytopenia).\n2. Hematologic malignancies.\n3. Thrombocytopenia caused by reasons other than chemotherapy, including but not limited to chronic liver disease, hypersplenism, infection, and hemorrhage, within 6 months prior to Study Day 1.\n4. Untreated brain metastases; or with leptomeningeal metastasis.\n5. Conditions that require emergent treatment (e.g., superior vena cava syndrome, spinal cord compression).\n6. Severe cardiovascular disorders or interventions within 6 months\n7. Have arterial\u002Fvenous thrombosis within 6 months\n8. Known bleeding disorders, platelet dysfunction\n9. Severe haemorrhage during screening\n10. Acute or uncontrolled hepatitis B\\&C infection\n11. Human immunodeficiency virus (HIV) infection.",{"count":181,"type":22},[161],"The study is being conducted to evaluate the efficacy, and safety of of Hetrombopag Olamine Tablets Vs Placebo in Patients with Chemotherapy-Induced Thrombocytopenia.",[244],"Patients With Chemotherapy-Induced Thrombocytopenia","2026-04-24",{"date":247,"type":34},"2026-04-30",{"date":249,"type":34},"2026-04-16",{"date":251,"type":22},"2029-06",{"name":40,"class":41},7,{"id":255,"slug":256,"hasResults":12,"nctId":257,"briefTitle":258,"officialTitle":259,"acronym":4,"eligibilityCriteria":260,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":261,"targetDuration":4,"studyType":23,"phases":262,"briefSummary":263,"conditions":264,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":107},"100627259","phase-2-safety-and-efficacy-of-hrs-9190-compared-to-cisatracurium-for-continuous-intravenous-infusion-in-adults-100627259","NCT07446309","Safety and Efficacy of HRS-9190 Compared to Cisatracurium for Continuous Intravenous Infusion in Adults","A Phase II, Multicenter, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Efficacy and Safety of Continuous Intravenous Infusion of HRS-9190 Versus Cisatracurium for Maintaining Neuromuscular Blockade During General Anesthesia in Adults Undergoing Elective Surgery.","Inclusion Criteria:\n\n1. Able and willing to provide a written informed consent\n2. Subjects requiring elective general anesthesia surgery\n3. Meet specified age and body mass index (BMI) criteria\n4. Conform to the ASA Physical Status Classification\n5. Use of highly effective contraception for a specified period if applicable\n\nExclusion Criteria:\n\n1. Scheduled for specific high-risk surgical procedures\n2. History of significant neuromuscular, cardiovascular, respiratory, or neurological disorders\n3. History of conditions affecting drug metabolism or anesthesia risk\n4. Abnormal laboratory values indicating significant clinical abnormalities\n5. Positive serology for specified infectious diseases\n6. Known hypersensitivity to related medications\n7. Recent use of medications interfering with neuromuscular function\n8. History of mental illness, cognitive impairment, or epilepsy\n9. Participation in another clinical trial within a specified period\n10. Any other condition deemed unsuitable by the investigator\n11. Pregnant or nursing women\n12. Unwilling to use birth control during the specified period",{"count":222,"type":22},[26],"The study will enroll adult patients scheduled for elective surgery requiring general anesthesia. Participants will be randomly assigned to receive either HRS-9190 for Injection or Cisatracurium. The primary objective is to measure the duration from cessation of the study drug infusion until the recovery of neuromuscular function to a specific level (TOFr ≥ 90%). Secondary objectives include onset time, duration of action, total time of adequate muscle relaxation during surgery, and neuromuscular recovery pattern.. Safety assessments will include monitoring of adverse events, vital signs, laboratory parameters, and other safety indicators throughout the study period. The hypothesis of this study is that HRS-9190 for Injection could provide effective neuromuscular relaxation, with a satisfied safety profile in the target patient population.",[265],"Neuromuscular Blockade","2026-04-22",{"date":268,"type":34},"2026-04-27",{"date":270,"type":22},"2026-04-10",{"date":272,"type":22},"2026-07",{"name":40,"class":41},{"id":275,"slug":276,"hasResults":12,"nctId":277,"briefTitle":278,"officialTitle":279,"acronym":4,"eligibilityCriteria":280,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":281,"targetDuration":4,"studyType":23,"phases":283,"briefSummary":284,"conditions":285,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":287,"lastUpdatePostDateStruct":288,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":293,"locationsCount":107},"100476333","phase-1-a-trial-of-injectable-shr-a1811-in-combination-with-pyrotinib-or-shr-1316-in-subjects-with-advanced-non-small-cell-lung-cancer-100476333","NCT05482568","A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer","Phase IB\u002FII Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Efficacy of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer With HER2","Inclusion Criteria:\n\n1. Ability to give informed consent, signed and dated IRB\u002FEC approved informed consent, willing and able to comply with treatment planning visits, tests and other procedural requirements\n2. When signing the informed consent, the age is 18-75 years old (including both ends), and there is no gender limitation\n3. The ECOG score is 0 or 1\n4. The expected survival is ≥12 weeks\n5. Subjects with advanced or metastatic non-small cell lung cancer\n6. Formalin fixed, paraffin-embedded tumor tissue blocks or sections of unstained tumor specimens are provided\n7. Subjects who have failed prior standard care or are intolerant to standard care\n8. There is at least one measurable lesion\n9. Vital organs are functioning well\n10. Heart function is good\n11. Agree to birth control\n\nExclusion Criteria:\n\n1. There are untreated or active central nervous system (CNS) tumor metastases\n2. Pleural, ascites, or pericardial effusion requiring intervention occurred within 7 days prior to initial administration\n3. Systemic antitumor therapy was performed 4 weeks prior to study initiation\n4. Prior treatment with antibody-conjugated drugs\n5. Received \\>30 Gy chest radiation within 6 months prior to initial administration\n6. Palliative radiotherapy was completed within 7 days prior to initial administration\n7. Failure to recover from toxicity and\u002For complications of previous interventions to nCI-CTCAE ≤1\n8. The half-life of CYP3A4 suppressor, moderate inhibitor or strong inducer or moderate inducer is less than 3 or less than 14 days from the date of first drug use, and the shorter is selected\n9. Received systemic immunosuppressant therapy within 14 days prior to the first study\n10. Subjects with known or suspected interstitial pneumonia\n11. In the first study, failure to swallow, chronic diarrhea, gastroenteritis, intestinal obstruction, gastrointestinal perforation, postgastrectomy, or colitis, or other medical conditions or special conditions affecting drug administration and absorption occurred within 28 days prior to administration\n12. Presence of any active, known or suspected autoimmune disease\n13. Have poorly controlled or severe cardiovascular disease\n14. Previous or concurrent malignancy\n15. Subjects who developed a severe infection within 28 days prior to the first dose\n16. Active hepatitis B\n17. There were active tuberculosis patients within 1 year before enrollment\n18. There is a history of immunodeficiency\n19. Live attenuated vaccine was administered within 28 days prior to initial study administration or is expected to be administered during study treatment\n20. Subjects who are participating in another clinical study or who have had their first dose less than 4 weeks since the end of the previous clinical study (last dose) or 5 half-lives of the study drug, whichever is shorter\n21. Major surgery other than diagnosis or biopsy was performed within 28 days prior to initial administration\n22. People who are known to be allergic to sir-A1811, pyrrolitinib, or any of the components of SIR-1316\n23. History of severe allergic reactions to other monoclonal antibody\u002Ffusion protein drugs\n24. Female subjects who are pregnant, breast-feeding, or planning to become pregnant during the study\n25. Uncontrolled mental illness and other conditions known to affect the completion of the study process, such as alcohol, drug or substance abuse and detention\n26. Any other conditions that, in the investigator's judgment, may increase the risk of study participation, interfere with study results, or make study participation unsuitable",{"count":282,"type":22},324,[25,26],"This study was an open, multicenter, dose-increasing\u002Finvestigational Phase IB\u002FII clinical trial to evaluate the efficacy of SHR-A1811 in combination with other antitumor therapies in subjects with advanced non-small cell lung cancer with HER2 . It can be divided into two parts, Part A is the dose escalation and efficacy exploration study of SHR-A1811 combined with Pyrotinib, and Part B is the dose escalation and efficacy exploration study of SHR-A1811 combined with SHR-1316.",[286],"Advanced Non-small Cell Lung Cancer","2026-04-17",{"date":289,"type":34},"2026-04-20",{"date":291,"type":34},"2022-09-15",{"date":63,"type":22},{"name":40,"class":41},{"id":295,"slug":296,"hasResults":12,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":4,"eligibilityCriteria":300,"healthyVolunteers":12,"sex":92,"minAge":18,"maxAge":301,"enrollmentInfo":302,"targetDuration":4,"studyType":23,"phases":303,"briefSummary":304,"conditions":305,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":107},"100624257","phase-1-a-clinical-study-of-shr-4394-in-combination-with-anti-tumor-therapy-in-prostate-cancer-100624257","NCT07407283","A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer","A Multicenter, Open-label, Phase Ib\u002FII Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of SHR-4394 in Combination With Anti-tumor Therapy in Participants With Prostate Cancer","Inclusion Criteria:\n\n1. Aged 18 to 85 years (inclusive) at the time of signing the informed consent form (with an upper age limit of 80 years for the dose escalation phase), and male.\n2. Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n3. Life expectancy is expected to be at least 12 weeks.\n4. Must have a prostate-specific antigen (PSA) level of ≥1 ng\u002FmL during the screening period.\n5. Ongoing therapy with a luteinizing hormone-releasing hormone analog (LHRHa) for medical castration or prior bilateral orchiectomy for surgical castration; participants who have not undergone bilateral orchiectomy must plan to maintain effective LHRHa therapy throughout the study period.\n6. Must have histologically or cytologically confirmed prostate adenocarcinoma, without a diagnosis of neuroendocrine carcinoma or small cell carcinoma.\n7. Must have radiographically confirmed metastatic disease by CT\u002FMRI or radionuclide bone scan (⁹⁹ᵐTc).\n8. Male participants with female partners of childbearing potential must practice highly effective contraception from the time of signing the informed consent form until 5 months after the last dose of the investigational product, and must refrain from donating sperm during this period.\n\nExclusion Criteria:\n\n1. Planning to receive any other anti-tumor therapy during the course of this study.\n2. Have received any other investigational drugs or treatments not yet approved for marketing within 4 weeks prior to the first dose in this study.\n3. Have undergone surgery requiring endotracheal intubation and general anesthesia within 28 days prior to the first dose, minor diagnostic or superficial surgery within 7 days prior to the first dose, or are scheduled to undergo elective surgery during the trial period.\n4. Have not recovered from adverse events due to prior anti-tumor therapy to ≤ Grade 1 according to NCI-CTCAE v6.0 (with the exception of Grade 2 peripheral neuropathy, alopecia, hypothyroidism controlled with hormone replacement therapy, and well-controlled type 1 diabetes managed with insulin).\n5. Known history of hypersensitivity to the investigational drug(s) to be used or any of their excipients.\n6. Participants with untreated or inadequately treated central nervous system (CNS) metastases, or uncontrolled or symptomatic active CNS metastases are excluded. However, participants may be eligible if their CNS metastases have been adequately treated, and any neurological symptoms have resolved or been stable for at least 4 weeks prior to enrollment (residual signs or symptoms related to the CNS treatment are allowed).\n7. Uncontrolled tumor-related pain, as determined by the investigator. Participants requiring analgesic medication must be on a stable analgesic regimen at the time of study entry.\n8. Presence of uncontrolled third-space effusions (e.g., pleural effusion, pericardial effusion, or ascites) that, despite therapeutic interventions such as drainage within 28 days prior to the first dose, remain uncontrolled or rapidly recur after drainage, requiring repeated drainage procedures.\n9. History of any other malignancy within 5 years prior to the first dose, with the exception of adequately treated basal cell or squamous cell carcinoma of the skin, radically resected papillary thyroid carcinoma, and radically resected ductal carcinoma in situ of the breast.\n10. History of epilepsy or any condition predisposing to seizures (such as transient ischemic attack, stroke, or traumatic brain injury with loss of consciousness requiring hospitalization) within 12 months prior to enrollment.\n11. History of interstitial pneumonia (ILD) or interstitial lung disease (including cases requiring steroid therapy), or any other history of pulmonary fibrosis, organizing pneumonia, drug- or radiation-induced pneumonitis, congenital pneumonitis, or any evidence of active pneumonia on chest CT scan that may interfere with the assessment of immune-related pulmonary toxicity.\n12. Active severe gastrointestinal disorders, including but not limited to complete or incomplete bowel obstruction, persistent\u002Frecurrent diarrhea (or diarrhea with fever), moderate to severe gastrointestinal hemorrhage (including endoscopically active bleeding), gastric or duodenal ulcers, gastrointestinal perforation, acute pancreatitis, ulcerative colitis, congenital megacolon, Crohn's disease, etc.\n13. Exclusion is required for: a history of severe infection within 4 weeks prior to the first dose; active infection requiring systemic antibiotics within 2 weeks prior to the first dose; or evidence of active tuberculosis infection within 1 year prior to enrollment. A history of active tuberculosis (TB) infection more than 1 year ago without adequate treatment is also excluded.\n14. Active hepatitis B virus or hepatitis C virus (HBV\u002FHCV) infection (HBsAg+ with DNA ≥ 2000 IU\u002FmL; HCV Ab+ with RNA \\> ULN).\n15. Participants are excluded if they have a history of immunodeficiency (including HIV positivity, other acquired or congenital immunodeficiencies) or organ transplantation, or a history of active autoimmune disease. Exceptions include participants with immune disorders not requiring systemic treatment (e.g., vitiligo, psoriasis) or autoimmune conditions well-controlled by hormone replacement therapy (e.g., type 1 diabetes, hypothyroidism).\n16. History of severe cardiovascular or cerebrovascular disease.\n17. History of arterial or venous thromboembolic events within 3 months prior to the first dose, or the presence of arterial\u002Fvenous thrombosis (e.g., deep vein thrombosis, pulmonary embolism) identified during screening.\n18. Any concomitant illness, condition, or social circumstance that, in the judgment of the investigator, could compromise participant safety or interfere with the completion of the study.","85 Years",{"count":95,"type":22},[25,26],"The study aims to assess the safety and tolerability of SHR-4394 in combination with anti-tumor therapy in participants with prostate cancer, and determine the recommended Phase II dose (RP2D); To evaluate of the efficacy of SHR-4394 in combination with anti-tumor therapy in participants with prostate cancer based on Prostate-Specific Antigen (PSA) response rate.",[99],{"date":307,"type":34},"2026-04-21",{"date":309,"type":34},"2026-04-08",{"date":311,"type":22},"2028-04",{"name":40,"class":41},{"id":314,"slug":315,"hasResults":12,"nctId":316,"briefTitle":317,"officialTitle":318,"acronym":4,"eligibilityCriteria":319,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":320,"enrollmentInfo":321,"targetDuration":4,"studyType":23,"phases":323,"briefSummary":324,"conditions":325,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":327,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":332,"locationsCount":42},"100595456","phase-1-a-clinical-study-to-evaluate-the-pharmacokinetic-and-pharmacodynamics-properties-of-of-shr-3167-in-subjects-with-type-2-diabetes-100595456","NCT07032688","A Clinical Study to Evaluate the Pharmacokinetic and Pharmacodynamics Properties of of SHR-3167 in Subjects With Type 2 Diabetes","A Clinical Study to Evaluate the Pharmacokinetic and Pharmacodynamics Properties of of SHR-3167 Injection at Steady State in Subjects With Type 2 Diabetes","Inclusion Criteria:\n\n1. Informed consent obtained before any trial-related activities.\n2. Age 18\\~59 years at screening (including cut-off values at both ends).\n3. Confirmed diagnosis of type 2 diabetes mellitus ≥ 6 months before screening.\n4. Female subjects of childbearing potential and their partners are male subjects of childbearing potential, who have no fertility plan and agree to take high-efficiency contraceptive measures within 3 months after signing the informed consent form and have no plans to donate eggs\u002Fsperm; Female subjects of childbearing potential have a negative pregnancy test during the screening period and are not lactating.\n\nExclusion Criteria:\n\n1. Poor blood pressure control at screening.\n2. Known or suspected allergy to investigational drug products or related products; or a history of multiple and\u002For severe allergies to drugs or foods.\n3. Serious cardiovascular and cerebrovascular diseases within 6 months prior to screening.\n4. Positive test for hepatitis B surface antigen (HBsAg), HIV antibody, treponema pallidum specific antibody, or hepatitis C virus antibody; or the investigator judges that the subject is in the incubation or active phase of the above infection.\n5. Malignancy or history of malignancy within 5 years prior to screening.\n6. Participation in any clinical trial of an approved or unapproved investigational drug\u002Fmedical device within 90 days prior to screening.\n7. Any other condition judged by the investigator to be likely to affect the subject's safety or interfere with the evaluation of trial results.","59 Years",{"count":322,"type":22},55,[25],"The objective of this study is to evaluate the pharmacokinetics and pharmacodynamics of SHR-3167 at steady state in subjects with type 2 diabetes.",[326],"Type 2 Diabetes",{"date":287,"type":34},{"date":329,"type":34},"2025-08-11",{"date":331,"type":22},"2027-04",{"name":40,"class":41},{"id":334,"slug":335,"hasResults":12,"nctId":336,"briefTitle":337,"officialTitle":338,"acronym":4,"eligibilityCriteria":339,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":340,"targetDuration":4,"studyType":23,"phases":342,"briefSummary":343,"conditions":344,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":348,"completionDateStruct":350,"leadSponsor":351,"locationsCount":42},"100622185","phase-1-a-clinical-study-on-the-safety-tolerability-pharmacokinetics-and-efficacy-of-shr-1049-in-patients-with-advanced-solid-tumors-100622185","NCT07380334","A Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-1049 in Patients With Advanced Solid Tumors","An Open Label, Multicenter Phase I Clinical Study on the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-1049 Injection in Patients With Advanced Solid Tumors","Inclusion Criteria:\n\n1. Voluntarily join this study, sign the informed consent form, have good compliance, and can cooperate with follow-up;\n2. Age range of 18-75 years old (including 18 and 75 years old, calculated on the day of signing informed consent), both male and female are eligible;\n3. Dose exploration stage: Participants with advanced or metastatic solid tumors diagnosed by tissue or cytological pathology who have failed standard treatment (disease progression or toxicity intolerance) or have no effective standard treatment;\n4. Stage of efficacy extension: Late stage or metastatic solid tumors diagnosed by tissue or cytological pathology;\n5. Able to provide sufficient fresh or archived tumor tissue specimens for third-party central laboratories designated by the sponsor to test expression levels; For participants who are unable to provide tumor tissue samples, the decision to enroll will be made after joint evaluation by the researchers and the sponsor;\n6. At least one measurable lesion that meets RECIST v1.1 criteria; Lesions that have undergone local treatment, if there is clear evidence of significant progression after treatment, can be selected as target lesions;\n7. ECOG PS score: 0 to 1;\n8. Expected survival period ≥ 12 weeks;\n9. The function of important organs meets the requirements;\n10. Female participants with fertility must have a negative serum HCG test within 7 days prior to their first medication and must be non lactating; Female participants with fertility must agree to use contraception and avoid egg donation for a period of 7 months from the signing of the informed consent form until the last administration of the investigational drug; Male participants whose partners are fertile women must agree to contraception and avoid donating sperm for a period of 4 months from the signing of the informed consent form until the last administration of the investigational drug.\n\nExclusion Criteria:\n\n1. Accompanied by untreated or active central nervous system (CNS) tumor metastasis; Participants with a history of meningeal metastasis or current meningeal metastasis;\n2. Imaging shows tumor invasion of large blood vessels or unclear boundary with blood vessels; Or it may be determined by researchers that the participant's tumor has a high possibility of invading important blood vessels and causing fatal massive bleeding during treatment;\n3. Previous or concurrent presence of other malignant tumors;\n4. Chest effusion, pericardial effusion, or abdominal effusion that is accompanied by clinical symptoms, difficult to control, or moderate or above; If fluid drainage is performed (excluding diagnostic puncture surgery), those who have been stable for at least 2 weeks after drainage can be included in the group;\n5. Interstitial pneumonia\u002Finterstitial lung disease, non infectious pneumonia (such as radiation pneumonitis) that previously required steroid treatment; Currently present or suspected of having interstitial pneumonia\u002Finterstitial lung disease, non infectious pneumonia, or other active pneumonia; Severe asthma, severe chronic obstructive pulmonary disease (COPD), restrictive lung disease, and other lung damage occurred within 6 months prior to the first use of medication; Individuals with active pulmonary tuberculosis;\n6. Accompanied by poorly controlled or severe cardiovascular disease;\n7. Within one month prior to the first medication, there has been a bleeding event with NCI-CTCAE v5.0 grade ≥ 2;\n8. Those who have experienced or are expected to experience gastrointestinal perforation or fistula, tracheal fistula, urethral fistula, or abdominal abscess within 3 months before the first medication;\n9. Symptoms and signs of gastrointestinal obstruction or gastrointestinal obstruction within 3 months prior to the first use of medication;\n10. Participants who have experienced a severe infection within one month prior to their first medication;\n11. History of immunodeficiency, including HIV test positive, other acquired or congenital immunodeficiency diseases, or a history of organ transplantation; Participants known to have active hepatitis or active hepatitis C;\n12. Patients who have previously undergone surgery (excluding diagnostic surgery), radiotherapy, local treatment, chemotherapy, macromolecular targeted therapy, anti-tumor immunotherapy, and have completed treatment (last medication) less than 4 weeks after the first medication; Small molecule targeted drugs (including other oral targeted drugs used in clinical trials) with less than 5 half lives or 4 weeks (whichever is shorter) between the last dose and the first dose;\n13. Previously received drug treatment with the same mechanism as the experimental drug;\n14. According to NCI-CTCAE v5.0 classification, those whose toxicity caused by previous anti-tumor therapy has not yet recovered to ≤ grade 1;\n15. Individuals known to be allergic to any component or other antibody drugs of SHR-1049 product;\n16. Those who have received attenuated live vaccine within 4 weeks before the first administration or are likely to receive attenuated live vaccine during treatment and within 60 days after the last administration;\n17. According to the researcher's judgment, there are other factors that may affect the research results or force the termination of this study midway.",{"count":341,"type":22},200,[25],"This study is a multicenter, open label, dose exploration\u002Fefficacy extension Phase I clinical trial aimed at evaluating the safety, tolerability, pharmacokinetics and efficacy of SHR-1049 injection in patients with advanced solid tumors.",[345],"Advanced Solid Tumor","2026-04-15",{"date":249,"type":34},{"date":349,"type":34},"2026-03-12",{"date":83,"type":22},{"name":40,"class":41},{"id":353,"slug":354,"hasResults":12,"nctId":355,"briefTitle":356,"officialTitle":357,"acronym":4,"eligibilityCriteria":358,"healthyVolunteers":12,"sex":50,"minAge":18,"maxAge":19,"enrollmentInfo":359,"targetDuration":4,"studyType":23,"phases":361,"briefSummary":362,"conditions":363,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":365,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":107},"100579750","phase-3-a-study-of-shr-a1811-in-subjects-with-ovarian-cancer-100579750","NCT06828354","A Study of SHR-A1811 in Subjects With Ovarian Cancer","An Open-label, Randomized, Multicenter Phase III Clinical Trial of SHR-A1811 Versus Investigator-selected Chemotherapy for Platinum-resistant Relapsed Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer","Inclusion Criteria:\n\n1. The subjects voluntarily joined the study and signed the Informed consent forms (ICF).\n2. Measurable disease, as defined by RECIST v1.1.\n3. The Eastern Cancer Cooperative Group (ECOG) performance status of 0 or 1.\n4. Life expectancy ≥ 12 weeks.\n\nExclusion Criteria:\n\n1. Symptomatic, untreated or active central nervous system metastases.\n2. Have uncontrolled or severe cardiovascular disease.\n3. With any active autoimmune disease or history of autoimmune disease.\n4. Patients with active hepatitis B or hepatitis C.\n5. Severe infections prior to initiation of study treatment.\n6. Patients with active tuberculosis.",{"count":360,"type":22},300,[161],"This is an open-label study to evaluate the safety and efficacy of SHR-A1811 for injection in subjects with ovarian cancer.",[364],"Ovarian Cancer",{"date":289,"type":34},{"date":367,"type":34},"2025-03-13",{"date":369,"type":22},"2027-12",{"name":40,"class":41},{"id":372,"slug":373,"hasResults":12,"nctId":374,"briefTitle":375,"officialTitle":376,"acronym":4,"eligibilityCriteria":377,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":378,"targetDuration":4,"studyType":23,"phases":380,"briefSummary":381,"conditions":382,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":383,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":389,"locationsCount":107},"100627247","phase-1-a-clinical-study-of-hrs-8364-in-the-treatment-of-advanced-solid-tumor-subjects-100627247","NCT07446153","A Clinical Study of HRS-8364 in the Treatment of Advanced Solid Tumor Subjects","An Open Label, Multicenter Phase I\u002FII Clinical Study on the Safety, Tolerability, Pharmacokinetics, and Efficacy of HRS-8364 in the Treatment of Advanced Solid Tumor Subjects","Inclusion Criteria:\n\n1. Voluntarily joining this study, signing an informed consent form, good compliance, and able to cooperate with follow-up.\n2. Age range: 18-75 years old (including boundary values), both males and females are eligible.\n3. Monotherapy dose escalation stage: advanced solid tumors diagnosed by cytology or histology, which have failed standard treatment or are intolerant to previous standard treatment or have no standard treatment.\n4. Monotherapy dose expansion stage: advanced solid tumors diagnosed by cytology or histology; with other systemic treatments during the recurrence or metastasis stage, and disease progression during or after treatment; The combined dose expansion phase allows for the inclusion of individuals who have not received prior treatment with immuno checkpoint inhibitors (ICIs).\n5. Efficacy expansion of monotherapy: advanced solid tumors diagnosed by histopathology or cytology; with other systemic treatments during the recurrence or metastasis stage, and disease progression during or after treatment.\n6. At least one measurable lesion that meets the RECIST v1.1 criteria.\n7. ECOG PS score: 0 to 1.\n8. Expected survival ≥ 12 weeks.\n9. Female subjects with reproductive ability and male subjects with partners who are reproductive women must agree to use efficient contraception during the trial period and within 30 days after the last dose of HRS-8364 (whichever comes later), have no fertility plan, and avoid donating eggs\u002Fsperm; Female subjects with fertility must have a negative blood pregnancy test within 7 days prior to the first administration and must be non-lactating.\n\nExclusion Criteria:\n\n1. Untreated brain metastases; Or accompanied by meningeal metastasis, spinal cord compression, etc.\n2. Large blood vessels invasion confirmed by imaging, or the subject's tumor has a high possibility of invading important blood vessels and causing fatal bleeding during treatment judged by researchers.\n3. Uncontrolled pleural effusion, pericardial effusion, or peritoneal effusion accompanied by clinical symptoms.\n4. Severe bone damage caused by tumor bone metastasis, including uncontrolled severe bone pain, pathological fractures in important areas that have occurred or are expected to occur in the past 6 months, and spinal cord compression. Subjects who require analgesic medication must have a stable analgesic treatment plan in place at the time of entry into the study.\n5. Other malignant tumors in the past 5 years or at the same time.\n6. Major arterial\u002Fvenous thrombotic events within 6 months prior to the first use of medication, such as cerebrovascular accidents (including temporary ischemic attacks, cerebral hemorrhage, cerebral infarction (excluding asymptomatic lacunar cerebral infarction)), deep vein thrombosis (excluding asymptomatic and non anticoagulant intramuscular vein thrombosis), and pulmonary embolism.\n7. Past or current active interstitial lung disease requiring treatment, non-infectious pneumonia requiring glucocorticoid systemic therapy (such as radiation pneumonitis); Currently, individuals with active pneumonia or confirmed severe pulmonary ventilation dysfunction through lung function tests.\n8. Individuals with active pulmonary tuberculosis. Individuals who have undergone sufficient treatment and have stopped anti tuberculosis treatment for at least 3 months prior to their first medication can be enrolled in the study.\n9. Known to have a positive history of human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS). Known to have active viral hepatitis.\n10. Unable to swallow pills normally or experiencing gastrointestinal dysfunction, which may affect drug absorption according to researchers' assessment.\n11. Individuals who have experienced intestinal obstruction or gastrointestinal perforation within 3 months prior to their first medication use.\n12. According to the researchers' assessment, there are other factors that may affect the research results or lead to the forced termination of this study, such as alcohol abuse, drug use, drug abuse, other serious illnesses (including mental illnesses) that require concurrent treatment, serious laboratory test abnormalities, and family or social factors that may affect medication safety.",{"count":379,"type":22},282,[25,26],"This study is an open, multicenter, Phase I\u002FII clinical trial, divided into three stages: dose escalation, dose expansion and efficacy expansion.",[29],{"date":384,"type":34},"2026-04-03",{"date":386,"type":34},"2026-03-19",{"date":388,"type":22},"2029-12",{"name":40,"class":41},{"id":391,"slug":392,"hasResults":12,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":4,"eligibilityCriteria":396,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":397,"targetDuration":4,"studyType":23,"phases":398,"briefSummary":399,"conditions":400,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":402,"startDateStruct":403,"completionDateStruct":405,"leadSponsor":407,"locationsCount":42},"100611529","phase-2-a-phase-ii-clinical-study-of-fh-006-for-injection-combined-with-other-anticancer-therapies-in-subjects-with-lung-cancer-100611529","NCT07241767","A Phase II Clinical Study of FH-006 for Injection Combined With Other Anticancer Therapies in Subjects With Lung Cancer","An Open Label, Multicenter Phase II Clinical Study on the Safety, Tolerability, and Efficacy of FH-006 Injection Combined With Other Anti-tumor Therapies in Lung Cancer Subjects","Inclusion Criteria:\n\n1. Age range: 18-75 years old (including both ends), gender is not limited.\n2. Subjects with locally advanced or metastatic non-small cell lung cancer confirmed by histology or cytology as unsuitable for radical surgery or radiotherapy treatment\n3. ECOG score is 0 or 1\n4. Expected survival period ≥ 12 weeks\n5. According to the RECIST v1.1 standard, there must be at least one measurable lesion.\n6. Good level of organ function\n7. The patient voluntarily joined this study and signed informed consent\n8. Left ventricular ejection fraction (LVEF) ≥ 50%\n\nExclusion Criteria:\n\n1. Suffering from other malignant tumors within the past 5 years\n2. Subjects with active central nervous system (CNS) tumor metastasis, a history of meningeal metastasis, or current meningeal metastasis\n3. Patients with uncontrollable tumor related pain\n4. Has serious cardiovascular and cerebrovascular diseases\n5. Significant clinically significant bleeding symptoms occurred within 3 months prior to the first study medication\n6. Uncontrollable third interstitial fluid accumulation within 2 weeks of initial study medication\n7. History of clinically significant pulmonary diseases\n8. Receive other anti-tumor treatments within 4 weeks before the first medication\n9. Severe infection within 4 weeks before the first medication\n10. Active, known or suspected autoimmune diseases, and a history of autoimmune diseases.\n11. History of immunodeficiency\n12. Individuals with active pulmonary tuberculosis infection within the year prior to enrollment\n13. Chest radiation therapy patients who received\\>30 Gy within 24 weeks prior to the first use of the investigational drug\n14. The adverse reactions of previous anti-tumor treatments have not yet recovered to ≤ Grade I\n15. Surgical treatment of important organs within 4 weeks prior to the first use of medication\n16. Use attenuated live vaccine within 28 days prior to the first use of the investigational drug\n17. There are other serious physical or mental illnesses or laboratory abnormalities present\n18. Pregnant, lactating women, or female participants who plan to become pregnant within 14 months after the last use of the investigational drug during the study period\n19. Having bleeding tendency, high risk of bleeding, coagulation dysfunction or thrombophilia tendency\n20. Previously experienced hypertensive crisis or hypertensive encephalopathy\n21. Suffering from significant vascular disease within 6 months prior to the first use of medication\n22. Have undergone a biopsy or other minor surgery within 7 days prior to the first use of medication\n23. Having severe, unhealed wounds, active ulcers, or untreated fractures\n24. Gastrointestinal perforation occurred within 6 months prior to the first use of medication\n25. 24-hour proteinuria quantification ≥ 1g within 7 days before the first medication\n26. CT\u002FMRI indicates tumor surrounding or invading large blood vessels",{"count":341,"type":22},[26],"Evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of FH-006 in combination with other anti-tumor treatments in lung cancer subjects, and determine the recommended dose (RP2D) and initial efficacy for phase II clinical trials.",[401],"Lung Cancer",{"date":309,"type":34},{"date":404,"type":34},"2025-11-12",{"date":406,"type":22},"2028-11",{"name":40,"class":41},{"id":409,"slug":410,"hasResults":12,"nctId":411,"briefTitle":412,"officialTitle":413,"acronym":4,"eligibilityCriteria":414,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":415,"targetDuration":4,"studyType":23,"phases":417,"briefSummary":418,"conditions":419,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":421,"lastUpdatePostDateStruct":422,"startDateStruct":424,"completionDateStruct":426,"leadSponsor":428,"locationsCount":42},"100620802","phase-2-the-efficacy-and-safety-of-shr4640-tablet-combined-with-40-mg-febuxostat-tablets-in-the-treatment-of-primary-gout-and-hyperuricemia-100620802","NCT07362355","The Efficacy and Safety of SHR4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia","A Multicenter, Randomized, Double-blind, Active-controlled Parallel-group Phase ii Clinical Study to Compare the Efficacy and Safety of SHR4640 Tablets Combined With Febuxostat Tablets at 40 mg\u002FDay Versus Febuxostat Tablets With Dose Escalation in Treatment of Primary Gout and Hyperuricemia Subjects With Inadequate Control on 40 mg\u002FDay Febuxostat","Inclusion Criteria:\n\n1. Voluntarily signed the informed consent, understood the procedures and methods of the study, and was willing to complete the study strictly in accordance with the clinical trial protocol;\n2. The screening age should be 18-75 years old (including both ends), male or female;\n3. Receive febuxostat at a stable dose of 40 mg\u002Fday for ≥6 weeks before randomization; have a fasting serum uric acid level ≥390 µmol\u002FL at the first measurement, and a repeat fasting serum uric acid level ≥360 µmol\u002FL after taking febuxostat 40 mg\u002Fday stably for ≥2 weeks during screening and run-in period,;\n4. Meet the gout classification criteria formulated by the American College of Rheumatology (ACR) in 1977 or the joint gout classification criteria formulated by the American College of Rheumatology and the European League Against Rheumatism (ACR\u002FEULAR) in 2015;\n5. Body Mass Index (BMI) between 18 kg\u002Fm² and 35 kg\u002Fm².\n\nExclusion Criteria:\n\n\\-\n\nSubjects who meet any of the following conditions will be excluded:\n\n1\\. General conditions:\n\n1. Pregnant or lactating women;\n2. Females of childbearing potential or males (except those whose partners are infertile) who refuse to use or use medically unapproved highly effective contraceptive measures within 6 months (for females) or 3 months (for males) from screening to the last dose of study medication;\n3. Average daily alcohol intake exceeding 14 g for females (e.g., 145 mL of wine, 497 mL of beer, or 43 mL of low-alcohol liquor) or exceeding 28 g for males (e.g., 290 mL of wine, 994 mL of beer, or 86 mL of low-alcohol liquor) within 1 month before screening;\n4. Drug abusers;\n5. Subjects with poor compliance judged by investigators, which may affect the safety and efficacy evaluation of the study drug.\n\n2\\. The following laboratory abnormalities within 4 weeks before randomization:\n\n1. Alanine aminotransferase (ALT) and\u002For aspartate aminotransferase (AST) and\u002For total bilirubin (TBIL) \\> 2 times the upper limit of normal (ULN);\n2. Estimated glomerular filtration rate (eGFR) \\\u003C 60 mL\u002F(min×1.73m²) calculated by the Modification of Diet in Renal Disease (MDRD) formula based on serum creatinine level;\n3. Glycated hemoglobin (HbA1c) ≥ 8%;\n4. Active hepatitis B \\[positive hepatitis B surface antigen (HBsAg) and hepatitis B virus deoxyribonucleic acid (HBV-DNA) exceeding the normal range\\], or positive anti-hepatitis C virus (HCV) antibody, or positive human immunodeficiency virus (HIV) antibody, or positive syphilis antibody test;\n5. White blood cell count \\\u003C 3.0×10⁹\u002FL, and\u002For hemoglobin \\\u003C 90 g\u002FL, and\u002For platelet count \\\u003C 80×10⁹\u002FL;\n6. Prolonged QTcF interval confirmed by repeated 12-lead electrocardiogram (ECG) (QTcF \\> 450 ms).\n\n3\\. History of or comorbidities with any of the following:\n\n1. Hypersensitivity to SHR4640 or any component of SHR4640, or a history of intolerance or contraindication to febuxostat or citrate;\n2. Secondary hyperuricemia caused by tumors, chronic kidney disease, hematological diseases, drugs, or other causes;\n3. Other joint lesions that investigators believe may confuse gouty arthritis, such as rheumatoid arthritis, suppurative arthritis, traumatic arthritis, psoriatic arthritis, pseudogout, systemic lupus erythematosus, or joint lesions caused by chemotherapy, radiotherapy, chronic lead poisoning, acute obstructive nephropathy, etc.;\n4. B-ultrasound suggesting or suspecting urinary calculi within 4 weeks before randomization;\n5. Gout flare within 2 weeks before randomization;\n6. History of active peptic ulcer within 1 year before screening and during the screening period, or active peptic ulcer at screening;\n7. History of xanthinuria;\n8. Suffering from malignant tumors, or a history of malignant tumors within 5 years before screening (except for treated non-melanoma skin cancers with no signs of recurrence and resected cervical intraepithelial neoplasia);\n9. History of chronic or recurrent infections within 1 year before screening and during the screening period; or severe infections (including but not limited to hepatitis, sepsis, pneumonia, pyelonephritis, etc.) or infections leading to hospitalization within 3 months before screening and during the screening period; or infections treated with intravenous antibiotics within 2 weeks before randomization; or open draining wounds or ulcers at screening and during the screening period;\n10. Subjects requiring systemic treatment with immunosuppressants;\n11. Past or current moderate to severe congestive heart failure (New York Heart Association Class III or IV);\n12. Myocardial infarction, unstable angina pectoris, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, transient ischemic attack, and other cardiovascular and cerebrovascular events leading to hospitalization within 1 year before screening and during the screening period;\n13. Poorly controlled hypertension at screening and during the screening period \\[resting systolic blood pressure (SBP) ≥ 180 mmHg and\u002For diastolic blood pressure (DBP) ≥ 110 mmHg, confirmed by re-examination\\];\n14. Complicated with other severe or poorly controlled diseases;\n15. Major surgery performed within 3 months before screening and during the screening period, or failure to recover after surgery, or plan to undergo major surgery during the study;\n16. Blood donation (or blood loss) with a volume ≥ 400 mL, or blood transfusion received within 3 months before screening and during the screening period;\n17. Other conditions deemed inappropriate for participation in this study by investigators.\n\n4\\. Use of any of the following drugs or participation in clinical trials:\n\n1. Participation in any clinical trial of investigational drugs (including investigational vaccines) and use of investigational drugs within 3 months before screening or within 5 half-lives of the investigational drug (whichever is longer);\n2. Participation in any clinical trial of medical devices within 3 months before screening (excluding subjects who failed screening);\n3. Use of other urate-lowering drugs (allopurinol, probenecid, benzbromarone, dotinurad, recombinant urate oxidase) within 4 weeks before screening;\n4. Use of drugs that interact with febuxostat (theophylline, azathioprine, mercaptopurine) within 4 weeks before screening;\n5. Daily aspirin dosage exceeding 100 mg or unstable dosage within 4 weeks before screening;\n6. Use of any diuretics within 2 weeks before randomization;\n7. Use of angiotensin II receptor blockers (e.g., losartan), calcium channel blockers (e.g., amlodipine), fibrate lipid-lowering drugs (e.g., fenofibrate), statin lipid-lowering drugs (e.g., atorvastatin), clofibrate, acetohexamide, or sodium-glucose cotransporter 2 (SGLT2) inhibitors (e.g., empagliflozin) with unstable dosages within 2 weeks before randomization.",{"count":416,"type":22},340,[26],"SHR4640 tablets is a highly selective and potent URAT1 inhibitors. The study is being conducted to evaluate the efficacy, and safety of SHR4640 tablet combined with 40 mg\u002Fd febuxostat tablet in reducing uric acid in subjects with primary gout and hyperuricemia The primary purpose of the study is to evaluate the efficacy and safety of the combination of SHR4640 and 40 mg\u002Fd febuxostat compared with 60 mg\u002Fd febuxostat in primary gout and hyperuricemia subjects with inadequate control on 40 mg\u002Fd febuxostat for 12 weeks.",[420],"Primary Gout and Hyperuricemia","2026-04-01",{"date":423,"type":34},"2026-04-07",{"date":425,"type":34},"2026-02-09",{"date":427,"type":22},"2027-07",{"name":40,"class":41},{"id":430,"slug":431,"hasResults":12,"nctId":432,"briefTitle":433,"officialTitle":434,"acronym":4,"eligibilityCriteria":435,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":301,"enrollmentInfo":436,"targetDuration":4,"studyType":23,"phases":437,"briefSummary":438,"conditions":439,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":349,"lastUpdatePostDateStruct":441,"startDateStruct":443,"completionDateStruct":445,"leadSponsor":446,"locationsCount":107},"100621615","phase-2-a-trial-of-tegileridine-fumarate-lnjection-for-prolonged-mechanical-ventilation-abirritation-in-the-intensive-care-unit-icu-100621615","NCT07372924","A Trial of Tegileridine Fumarate Lnjection for Prolonged Mechanical Ventilation Abirritation in the Intensive Care Unit (ICU)","A Phase II, Multicenter, Randomized, Single-Blind, Dose Exploration, Positive Comparator Study to Evaluate the Efficacy and Safety of Tegileridine Fumarate Lnjection for Prolonged Mechanical Ventilation Abirritation in the Intensive Care Unit (ICU)","Inclusion Criteria:\n\n1. Patients or their guardians are able to provide a written informed consent\n2. Subjects have been treated with endotracheal intubation and mechanical ventilation ≤24h, and then prolonged mechanical ventilation ≥48h in the next\n3. Age ≥ 18 and ≤ 85 years, Male or female\n4. Body mass index (BMI) \\> 18 and \\\u003C 30 kg\u002Fm2\n5. Use of highly effective contraception for a specified period if applicable\n\nExclusion Criteria:\n\n1. Those who are known or suspected to be allergic or contraindicated to various components of the experimental drugs involved in the research institute\n2. With an expected survival time of less than 48 hours\n3. unable to undergo CPOT and RASS assessments due to various reasons, such as a history of psychiatric disorders, neurological disorders, neurological dysfunction, and consciousness disorders, as well as blindness, deafness, or aphasia\n4. Myasthenia gravis, bronchial asthma attack, acute intestinal obstruction, abdominal compartment syndrome\n5. Multiple organ failure\n6. Malignant tumor Subjects who received radiotherapy, chemotherapy, targeted therapy, and immunotherapy within the first month of randomization\n7. Chronic pain requires long-term use of analgesics\n8. Severe liver dysfunction\n9. Severe renal dysfunction\n10. Severe renal dysfunction\n11. Need to receive deep sedation or use neuromuscular blocking drugs\n12. Surgery or tracheotomy may be required during the study administration period\n13. Used monoamine oxidase inhibitors within the two weeks randomization\n14. History of drug abuse, drug use, alcohol abuse, and long-term use of psychotropic drugs within 2 years prior to the start of the screening period\n15. QTc abnormality during screening period\n16. Positive result for infectious disease\n17. Positive screening for drug abuse\n18. Pregnant or nursing women;\n19. Subjects who has Participated in any other clinical trials within the first 3 months of randomization\n20. Other conditions deemed unsuitable to be included.",{"count":21,"type":22},[26],"The purpose of this study is to evaluate the efficacy and safety of Tegileridine Fumarate lnjection for prolonged abirritation(48h to 72h) during mechanical ventilation in the ICU.",[440],"Abirritation in the ICU",{"date":442,"type":34},"2026-03-13",{"date":444,"type":22},"2026-02-24",{"date":272,"type":22},{"name":40,"class":41},{"id":448,"slug":449,"hasResults":12,"nctId":450,"briefTitle":451,"officialTitle":452,"acronym":4,"eligibilityCriteria":453,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":454,"targetDuration":4,"studyType":23,"phases":456,"briefSummary":457,"conditions":458,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":460,"lastUpdatePostDateStruct":461,"startDateStruct":462,"completionDateStruct":464,"leadSponsor":466,"locationsCount":42},"100556770","phase-2-a-study-of-bupivacaine-liposome-injection-in-the-treatment-of-pain-after-thoracoscopic-surgery-100556770","NCT06529432","A Study of Bupivacaine Liposome Injection in the Treatment of Pain After Thoracoscopic Surgery","Efficacy, Safety and Pharmacokinetics of Bupivacaine Liposome Injection for Paravertebral Nerve Block in the Treatment of Postoperative Pain After Thoracoscopic Surgery: a Multicenter, Randomized, Double-blind, Dose-finding, Positive Control, Phase Ⅱ Clinical Trial","Inclusion Criteria:\n\n1. Subjects who are willing to strictly follow the clinical trial protocol to complete this study and voluntarily sign informed consent;\n2. Elective surgical subjects undergoing lobectomy by single-aperture thoracoscope under general anesthesia;\n3. age ≥18 years old , Male or female;\n4. 18 kg\u002Fm2≤BMI≤30 kg\u002Fm2;\n5. ASA Physical Status Classification I-II;\n6. Female subjects of childbearing potential must agree to use contraception and refrain from egg donation from the signing of the informed consent form until 30 days after the last dose of the investigational drug. Serum or urine pregnancy tests must be negative before dosing and during the trial, and they must not be lactating. Male subjects with partners of childbearing potential must agree to use contraception and refrain from sperm donation from the signing of the informed consent form until 30 days after the last dose of the investigational drug.\n\nExclusion Criteria:\n\nParticipants with any of the following criteria were excluded from the study：\n\n1. Pre-existing and combined diseases:\n\n(1) Subjects with a history of myocardial infarction or unstable angina pectoris, or a history of severe arrhythmias such as atrioventricular block of degree II and above, or NYHA grade II and above in the 6 months before randomization; (2) Subjects with a history of ischemic stroke or transient ischemic attack (TIA); (3) Subjects with psychiatric disorders (such as schizophrenia, depression, etc.) and cognitive dysfunction; (4) Subjects with sensory disorders such as hyperalgesia; (5) Subjects with other physical pain witch may affect the evaluation of postoperative pain; (6) Subjects with airway or spinal anatomic factors caused by obstruction of ventilation, bronchiectasis, severe intraoperative thoracic adhesion, etc.\n\n2\\. Laboratory and other tests:\n\n1. Abnormal laboratory results during screening.\n\n   •Fasting blood glucose (FPG) ≥10.0mmol\u002FL.\n\n   •Abnormal liver function: aspartate aminotransferase (AST) or\u002Fand alanine aminotransferase (ALT) and\u002For total bilirubin (TBIL) ≥1.5×ULN.\n   * Abnormal renal function: serum creatinine (Cr) ≥1.5×ULN, or dialysis subjects.\n   * Abnormal coagulation function: PT\\> upper normal value +3s and\u002For APTT \\> upper normal value +10s.\n   * Platelet (PLT) \\\u003C80×109\u002FL.\n   * Hemoglobin concentration (Hb) \\\u003C 70g\u002FL.\n2. Screening period heart rate \\\u003C 50 beats\u002Fmin or heart rate \\> 100 beats\u002Fmin; 12-lead ECG QTc interval prolonged: male ≥450ms, female ≥470ms.\n3. Subjects with refractory hypertension or a history of refractory hypertension before randomization.\n\n3\\. Combined drugs:\n\n1. Subjects who allergic to or contraindicated with bupivacaine, other amide local anesthetics, and other drugs that may be used during the trial (e.g., propofol, remazolam, opioids, etc.).\n2. Subjects who used any of the following drugs within 5 drug half-lives prior before randomization (drug half-lives are based on actual drug instructions, or at least 48 hours of elution if half-lives are unknown):\n\n   * Class III antiarrhythmic drugs such as amiodarone.\n   * Drugs that affect liver metabolism: strong CYP1A2 inhibitors such as ciprofloxacin, enoxacin, fluvoxamine; CYP1A2 substrates: such as theophylline, imipramine; Strong CYP3A4 inhibitors such as voriconazole, ketoconazole, Ritonavir; CYP3A4 substrates such as darunavir, Indinavir, saquinavir; Strong CYP3A4 inducers such as rifampin.\n   * Intravenous or oral corticosteroids.\n   * Sedative drugs: benzodiazepines (such as diazepam, flurazepam, oxazepam, cloazepine, triazolam, alprazolam, esazolam, midazolam, etc.), barbiturates, carbamazepine, phenytoin, magnesium sulfate, chloral hydrate, etc..\n   * Pain relief and other drugs: Nonsteroidal anti-inflammatory drugs (aspirin is permitted for the prevention of cardiovascular events, provided it is used steadily for at least 30 days prior to randomization, Daily dose ≤100mg\u002F day), opioid agonists\u002Fantagonists, central alpha-adrenergic agonists (e.g. Clonidine, dexmedetomidine), anticonvulsants (e.g. Carbamazepine, pregabalin, gabapentin), antidepressants (e.g. Tricyclic, selective 5-HT reuptake inhibitors).\n\n     4\\. Others:\n\n(1) Subjects had a history of substance abuse, drug use, and\u002For alcohol abuse within the 1 year prior to randomization, with alcohol abuse defined as drinking an average of more than 2 units of alcohol per day (1 unit =360mL beer or 45mL liquor with 40% alcohol or 150 ml wine); Or consume alcoholic food or drink within 24 hours before receiving the study drug.\n\n(2) Subjects consumed excessive amounts of tea, coffee, grapefruit\u002Fgrapefruit juice, grapefruit juice, caffeinated beverages (averaging more than 8 cups per day, 200 mL per cup) in the 14 days prior to randomization.\n\n(3) Subjects who have participated in other clinical trials as subjects, and\u002For previously received investigational drug or device in this clinical trial within the 3 months prior to randomization.\n\n(4) Subjects who have any other factors deemed unsuitable for participation in this trial by the investigator.",{"count":455,"type":22},96,[26],"The objective of this study is to evaluate the efficacy, safety, and tolerability of bupivacaine liposomes for paravertebral nerve block in the treatment of thoracoscopic postoperative pain, and to evaluate the relevant human pharmacokinetics.",[459],"Local Analgesia Via Nerve Block","2026-03-10",{"date":349,"type":34},{"date":463,"type":34},"2026-03-03",{"date":465,"type":22},"2026-11",{"name":40,"class":41},{"id":468,"slug":469,"hasResults":12,"nctId":470,"briefTitle":471,"officialTitle":472,"acronym":4,"eligibilityCriteria":473,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":474,"targetDuration":4,"studyType":23,"phases":475,"briefSummary":476,"conditions":477,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":479,"lastUpdatePostDateStruct":480,"startDateStruct":482,"completionDateStruct":484,"leadSponsor":485,"locationsCount":42},"100607545","phase-1-a-study-of-hrs-2329-in-participants-with-advanced-solid-tumors-harboring-ras-mutations-or-amplifications-100607545","NCT07189949","A Study of HRS-2329 in Participants With Advanced Solid Tumors Harboring RAS Mutations or Amplifications","A Phase I Study of HRS-2329 Evaluating Safety, Tolerability, and Pharmacokinetics in Subjects With Advanced Solid Tumors Harboring RAS Mutations or Amplifications","Inclusion Criteria:\n\n1. Have fully understood this study and are willing to sign the ICF, with good compliance and cooperation in follow-up;\n2. Aged between 18-75 years old;\n3. Participants with histologically\u002Fcytologically confirmed advanced solid tumors who have been previously tested or are confirmed by the central laboratory to harbor RAS mutations or amplifications and have failed standard treatment;\n4. ECOG performance status (PS) score of 0 or 1;\n5. Life expectancy \\> 3 months;\n6. At least one measurable lesion per RECIST v1.1;\n7. Adequate organ function.\n\nExclusion Criteria:\n\n1. Toxicity (e.g., gastrointestinal reaction and skin toxicity) from prior anti-tumor treatment has not recovered to Grade ≤ 1 or a level specified in the inclusion\u002Fexclusion criteria;\n2. Presence of central nervous system (CNS) metastases;\n3. Participants with gastrointestinal diseases that affect drug administration\u002Fabsorption;\n4. Participants who have undergone major surgery other than diagnosis or biopsy within 28 days before the first dose, or are expected to undergo major surgery during the study period;\n5. Presence of serious pulmonary diseases;\n6. Active tuberculosis or a history of active tuberculosis infection within 48 weeks prior to screening, regardless of whether they have been treated;\n7. Active or persistent gastrointestinal bleeding within 6 months prior to screening;\n8. History of allogeneic bone marrow or solid organ transplantation;\n9. History of deep vein thrombosis or pulmonary embolism within 6 months prior to screening;\n10. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring clinical intervention;\n11. Positive human immunodeficiency virus (HIV) (HIV1\u002F2 antibodies), active chronic hepatitis B, or active hepatitis C (positive HCV antibody and positive HCV RNA);\n12. Known history of hypersensitivity to any component of the drug product to be used in the study.",{"count":21,"type":22},[25],"This is an open-label, multi-center phase I clinical study to evaluate the safety, tolerability, and pharmacokinetics of HRS-2329 in participants with advanced solid tumors harboring RAS mutations or amplifications.",[478],"Advanced Solid Tumors Harboring RAS Mutations or Amplifications","2026-03-05",{"date":481,"type":34},"2026-03-06",{"date":483,"type":34},"2025-10-16",{"date":83,"type":22},{"name":40,"class":41},{"id":487,"slug":488,"hasResults":12,"nctId":489,"briefTitle":490,"officialTitle":491,"acronym":4,"eligibilityCriteria":492,"healthyVolunteers":12,"sex":92,"minAge":18,"maxAge":93,"enrollmentInfo":493,"targetDuration":4,"studyType":23,"phases":495,"briefSummary":496,"conditions":497,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":498,"lastUpdatePostDateStruct":499,"startDateStruct":500,"completionDateStruct":502,"leadSponsor":503,"locationsCount":107},"100610632","phase-2-a-study-of-shr3680-hs-20093-and-shr2554-in-subjects-with-prostate-cancer-100610632","NCT07230106","A Study of SHR3680, HS-20093 and SHR2554 in Subjects With Prostate Cancer","A Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Efficacy of HS-20093 or SHR2554 Tablets in Combination With Novel Hormonal Agents in Participants With Metastatic Prostate Cancer","Inclusion Criteria:\n\n1. Voluntarily participate in this clinical study, understand the research procedures, and are able to provide written informed consent.\n2. Aged 18 to 80 years (inclusive), male.\n3. ECOG performance status of 0 or 1.\n4. Expected survival time ≥12 weeks.\n5. Histologically or cytologically confirmed prostate adenocarcinoma, with no features of neuroendocrine carcinoma or small cell carcinoma.\n6. Able to provide sufficient tumor tissue samples for retrospective genetic testing.\n7. Ongoing Androgen Deprivation Therapy (ADT) throughout the study period, i.e., continuous treatment with a GnRH agonist or antagonist (chemical castration) or prior bilateral orchiectomy (surgical castration).\n8. PSA level ≥1 ng\u002Fml at screening.\n9. Adequate organ function levels at baseline assessment.\n10. Male participants with female partners of childbearing potential must agree to refrain from sperm donation and use effective contraception from the time of signing the informed consent form until 4.5 months after the last dose of HS-20093 or 3 months after the last dose of other study treatments, whichever is later.\n\nExclusion Criteria:\n\n1. Known hypersensitivity or intolerance to the investigational drug(s) or their excipients.\n2. Adverse events from prior anti-tumor therapy have not recovered to Grade ≤1 as per CTCAE v5.0.\n3. Administration of estrogen, progesterone, or 5-alpha reductase inhibitors within 28 days prior to enrollment.\n4. Administration of herbal medicines known to have anti-prostate cancer or PSA-lowering effects within 14 days prior to enrollment.\n5. Major surgery within 28 days prior to enrollment; palliative radiotherapy within 14 days prior to enrollment; or traumatic minor surgery within 7 days prior to enrollment.\n6. Pathological fractures in critical locations, spinal cord compression, etc., within the recent 6 months.\n7. Non-healing wounds, untreated fractures, or severe bone damage due to metastatic disease.\n8. Poorly controlled tumor-related pain.\n9. Dysphagia or other conditions significantly affecting drug absorption.\n10. Known central nervous system metastases or primary brain tumors.\n11. Significant pericardial, pleural, or peritoneal effusion requiring intervention.\n12. Severe cardiovascular or cerebrovascular diseases.\n13. Moderate to severe pulmonary disease significantly affecting respiratory function.\n14. Poorly controlled diabetes.\n15. Serious active infections within 14 days prior to enrollment.\n16. Active Hepatitis B, Hepatitis C, HIV, or immunodeficiency diseases.\n17. History of other malignancies within 5 years prior to enrollment.\n18. Any other condition deemed by the investigator to potentially affect the study.",{"count":494,"type":22},218,[26],"This is a phase II, multicentre clinical study investigating HS-20093 or SHR2554 in combination with a Novel Hormonal Agent (NHA) for advanced prostate cancer. The trial comprises two cohorts.",[99],"2026-02-28",{"date":463,"type":34},{"date":501,"type":34},"2025-12-08",{"date":388,"type":22},{"name":40,"class":41},{"id":505,"slug":506,"hasResults":12,"nctId":507,"briefTitle":508,"officialTitle":509,"acronym":4,"eligibilityCriteria":510,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":511,"targetDuration":4,"studyType":23,"phases":513,"briefSummary":514,"conditions":515,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":517,"lastUpdatePostDateStruct":518,"startDateStruct":520,"completionDateStruct":521,"leadSponsor":523,"locationsCount":42},"100612285","phase-2-a-trial-of-shr0302-tablets-and-shr0302-base-gel-in-patients-with-non-segmental-vitiligo-100612285","NCT07251595","A Trial of SHR0302 Tablets and SHR0302 Base Gel in Patients With Non-segmental Vitiligo","A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR0302 Tablets as Single Therapy or in Combination With SHR0302 Base Gel in the Treatment of Patients With Non-segmental Vitiligo","Inclusion Criteria:\n\n1. Sign the informed consent form before the clinical trial.\n2. On the day of signing the informed consent form, the age must be between 18 and 75 years old (inclusive), and it can be either male or female.\n3. The subjects and their partners had no intention of having children during the study period and within one month after the administration of the drug, did not donate sperm or eggs, and voluntarily adopted effective contraceptive measures. The serum pregnancy test results of the female subjects must be negative and they must not be in the lactation period.\n4. During the screening process, it was clinically diagnosed as non-segmental vitiligo.\n5. Throughout the entire research process, the participants agreed to stop using all treatments related to vitiligo as well as any cosmetic products with therapeutic effects.\n\nExclusion Criteria:\n\n1. Subjects diagnosed with segmental, mixed or undifferentiated vitiligo; or subjects previously diagnosed with other skin pigmentation disorders.\n2. When the facial skin lesions caused by vitiligo cover more than 33% of the area with white hair.\n3. During the screening period or at the baseline, there were other active skin lesions or skin infections that might interfere with the use of the study drug or the evaluation of the drug's efficacy.\n4. Subjects with a history of related infections\u002Fcommunicable diseases or infection\u002Fcontagion history.\n5. Known or suspected history of immunosuppression.\n6. Tuberculosis (TB) or latent tuberculosis infection.\n7. Positive for human immunodeficiency virus antibody HIV-Ab, positive for syphilis-specific antibody, positive for hepatitis C virus antibody HCV-Ab, or hepatitis B virus (HBV) infection.\n8. Subjects who have malignant tumors or have a history of malignant tumors.\n9. Abnormal thyroid function, with a history of thrombotic diseases within the previous 12 months, and having experienced a cardiovascular or cerebrovascular event that required hospitalization within the previous 12 months.\n10. There are serious abnormalities in the cardiovascular, mental, renal, liver, immune, gastrointestinal, urogenital, nervous, skeletal-muscular, skin, sensory, endocrine or hematological systems.\n11. Pregnant women, lactating women, or female participants who plan to become pregnant during the study period.\n12. Those who are known to be allergic to the test drug or any component of the test drug.",{"count":512,"type":22},176,[26],"The study is being conducted to evaluate the efficacy, and safety of SHR0302 tablets as single therapy or in combination with SHR0302 Base gel for patients with non-segmental vitiligo.",[516],"Non-segmental Vitiligo","2026-02-14",{"date":519,"type":34},"2026-02-18",{"date":209,"type":34},{"date":522,"type":22},"2027-09",{"name":40,"class":41},""]